




















































patients	 were	 exposed	 to	 the	 checklist,	 whilst	 7508	 (16.8%)	 sustained	 ≥1	 postoperative	
complications	and	207	(0.5%)	died	before	hospital	discharge.	Checklist	exposure	was	associated	with	
reduced	mortality	 (OR	 0.49	 [0.32-0.77];	 p<0.01),	 but	 no	 difference	 in	 complication	 rates	 (OR	 1.02	
[0.88-1.19];	p=0.75).	In	the	systematic	review,	we	screened	3,732	records	and	identified	11	eligible	
studies	of	453,292	patients	including	the	ISOS	cohort.	Checklist	exposure	was	associated	with	both	









More	 than	 310	 million	 surgical	 procedures	 are	 carried	 out	 worldwide	 every	 year.1	 Estimates	 of	
morbidity	 and	 mortality	 vary.2-4	 However,	 recent	 data	 suggest	 that	 ~75	 million	 patients	 will	
experience	a	postoperative	complication,	 leading	 to	 two	million	deaths	each	year.5,6	An	 important	
cause	 of	 avoidable	 harm	 is	 healthcare	 acquired	 illness	 or	 injury.	 In	 the	 United	 Kingdom	 (UK),	
perioperative	adverse	events	account	for	one	in	six	patient	safety	incidents,7	and	as	many	as	half	are	
potentially	avoidable.8	Preventable	adverse	events	are	costly	in	both	human	and	financial	terms.	The	
UK	 Department	 of	 Health	 estimates	 that	 iatrogenic	 harm	 costs	 the	 National	 Health	 Service	more	
than	£1bn	each	year,9	and	other	developed	countries	are	likely	to	be	exposed	to	similar	costs.		
	
Checklists	 are	 a	 simple	 and	 reproducible	way	 to	 standardise	 selected	 aspects	 of	 patient	 care.	 The	
World	Health	Organisation	(WHO)	Surgical	Safety	Checklist	is	the	most	widely	used	surgical	checklist,	
consisting	 of	 19	 items	 in	 three	 domains:	 before	 induction	 of	 anaesthesia,	 before	 surgical	 incision,	
and	before	 the	patient	 leaves	 the	operating	 theatre.	Actions	 include	 checks	 for	 a	 variety	of	 items	
including	 patient	 identity,	 introducing	 all	 team	 members,	 and	 antibiotic	 prophylaxis.10	 Since	 it’s	
inception,	 the	 checklist	 has	 been	 adopted	 in	 more	 than	 4000	 hospitals	 worldwide,11	 and	 is	 now	
considered	a	surrogate	marker	for	quality	of	patient	care.12	However,	there	is	only	limited	evidence	
of	any	effect	of	checklist	use	on	health	outcomes.12	A	previous	meta-analysis	 reported	 insufficient	























ISOS	 was	 a	 seven-day	 international	 cohort	 study,	 the	 main	 results	 of	 which	 have	 been	 reported	





August	2014.	Patients	undergoing	emergency	 surgery,	day-case	 surgery	or	 radiological	procedures	
were	excluded.	During	the	one-week	study	period,	data	were	collected	for	consecutive	patients	until	
hospital	discharge,	using	standardised	paper	case	record	forms.	Data	included	baseline	demographic	
information,	 details	 of	 the	 surgical	 procedure,	 postoperative	 care	 and	 in-hospital	 postoperative	






The	 primary	 outcome	measure	 for	 the	 analysis	 of	 the	 ISOS	 cohort	 was	 in-hospital	 mortality.	 The	




deemed	 to	 have	 met	 the	 secondary	 outcome:	 surgical	 site	 infection,	 body	 cavity	 infection,	
pneumonia,	 urinary	 tract	 infection,	 blood	 stream	 infection,	 myocardial	 infarction,	 arrhythmia,	







ten	participating	hospitals.	We	dichotomised	 the	 sample	 according	 to	 the	presence	or	 absence	of	




factors.	 For	 the	 adjusted	 analysis,	we	used	 a	 hierarchical	 two-level	 generalised	 linear	model,	with	
patients	at	the	first	level	and	hospitals	at	the	second	level;	a	three-level	model	with	countries	at	the	
third	 level	 did	 not	 converge.	 We	 included	 the	 following	 pre-specified	 covariates	 to	 adjust	 for	
potential	 confounding:	 age,	 gender,	 current	 smoker,	 American	 Society	 of	 Anesthesiologists	 (ASA)	
physical	 status	 score,	 grade	 of	 surgery,	 surgical	 procedure	 category,	 and	 presence	 of	 co-morbid	
disease	 (coronary	 artery	 disease,	 heart	 failure,	 diabetes	 mellitus,	 chronic	 obstructive	 pulmonary	
disease/asthma,	 cirrhosis,	metastatic	 cancer,	 stroke	 and	other	 unspecified	 chronic	 disease).	 These	
covariates	were	 selected	 for	 clinical	 plausibility	 and	 evidence	 of	 association	with	 the	 exposure	 or	












We	were	 interested	 to	assess	whether	 countries	with	high	 checklist	usage,	 as	 a	proportion	of	 the	
total	number	of	patients	(i.e.	checklist	compliance),	were	more	likely	to	have	lower	risk	of	in-hospital	
mortality	 or	 postoperative	 complications.	 We	 calculated	 checklist	 compliance	 by	 country	 as	 the	
proportion	of	patients	in	each	country	that	were	exposed	to	the	checklist.	We	ranked	countries	by	
compliance	and	divided	the	sample	into	four	similarly	sized	quartiles,	with	quartile	one	representing	
lowest	 compliance	 and	 quartile	 four	 representing	 highest	 compliance.	 We	 repeated	 the	 primary	
analysis	 using	 quartiles	 of	 checklist	 compliance	 as	 the	 exposure	 of	 interest,	 using	 a	 deviation	
contrast	where	the	mean	compliance	 for	 the	whole	cohort	was	treated	as	 the	reference	category.	
Secondly,	to	identify	whether	a	relationship	between	checklist	use	and	postoperative	complications	
or	mortality	differed	according	to	income	status	of	the	country	of	origin,	we	stratified	the	sample	by	




We	 undertook	 a	 systematic	 review	 and	 meta-analysis	 of	 the	 published	 literature	 describing	 the	
effects	of	surgical	safety	checklist	use	on	patient	outcomes,	including	the	results	of	the	ISOS	study.	
We	 prospectively	 registered	 the	 systematic	 review	 with	 PROSPERO	 (2016:CRD42016039878).	 The	
primary	outcome	was	mortality,	which	we	expected	 to	be	 the	most	 frequently	 reported	outcome	
measure.	The	secondary	outcome	was	postoperative	complications.	Definitions	of	complications	for	




(hdas.nice.org.uk).	 We	 scanned	 the	 bibliographies	 of	 included	 studies	 and	 consulted	 experts	 to	
identify	studies	 that	were	missed	by	 the	search.	Full	details	of	 the	search	strategy	are	provided	 in	




surgery,	 and	 reported	 either	 complications	 or	 mortality	 as	 postoperative	 outcomes.	 We	 did	 not	
include	 studies	where	 the	 surgical	 safety	 checklist	was	 tested	with	 another	 intervention	or	where	
the	checklist	was	modified.21	Differences	 in	opinion	were	resolved	through	discussion	and	referred	
to	 a	 third	 investigator	 (MG).	 Data	 were	 extracted	 from	 the	 selected	 papers	 by	 two	 independent	
investigators	 (MP	 and	 AF)	 to	 a	 pre-formatted	 Excel	 worksheet	 (Microsoft,	 Redmond,	 USA).	 The	
meta-analysis	 was	 conducted	 using	 Review	 Manager	 version	 5.3	 (Cochrane	 Collaboration,	
Copenhagen,	Denmark).	Risk	of	bias	was	assessed	using	the	Cochrane	tool	for	randomised	controlled	
trials,	 the	 National	 Institutes	 of	 Health	 ‘Quality	 Assessment	 of	 Before-and-after	 studies’	 tool	 for	
before	 and	 after	 studies,	 and	 the	 Newcastle	 Ottawa	 Scale	 for	 other	 non-randomised	 studies.22-24	
Between	 study	 heterogeneity	was	 assessed	with	 Chi-squared	 and	 I2	 tests	 using	 p<0.1	 as	 the	 pre-







We	 included	 44,814	 ISOS	 participants	 from	 497	 hospitals	 in	 27	 countries	 in	 this	 analysis	

















[0.45-0.83];	 p<0.01)	 (Table	 3),	with	 the	whole	 cohort	 as	 the	 reference	 category.	National	 rates	 of	
checklist	use	(quartile	1	and	4)	were	not	associated	with	any	effects	on	postoperative	complication	
rates.	When	we	stratified	the	sample	by	income	status	of	the	participating	country	and	repeated	the	
primary	analysis,	 the	 findings	 remained	similar	 (Supplementary	 tables	4	and	5).	To	 further	explore	
the	 absence	 of	 association	 between	 checklist	 use	 and	 reduced	 incidence	 of	 postoperative	
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random	effects	meta-analysis,	 checklist	 exposure	was	 associated	with	 reduced	mortality	 (OR	 0.75	
[0.62-0.92];	p<0.01;	I2=87%)	(Figure	1).	The	definition	of	mortality	was	‘in-hospital’	in	two	studies,	in-
hospital	 restricted	 to	30	days	 in	 five	 studies,	 and	 in-hospital	 restricted	 to	60	days	 in	one	 study.	 In	
contrast,	 12,054/161,858	 (7.4%)	 of	 patients	 exposed	 to	 the	 checklist	 developed	 postoperative	
complications,	 compared	 to	 6,043/123,329	 (4.9%)	 of	 patients	 not	 exposed	 to	 the	 checklist.	 In	 the	
random	effects	meta-analysis,	checklist	exposure	was	associated	with	a	reduced	incidence	of	post-




The	 risk	 of	 bias	was	 low	 in	 all	 included	 studies	 (Supplementary	 table	 7)	 and	 visual	 assessment	 of	
funnel	 plots	 demonstrated	 no	 evidence	 of	 publication	 bias.	 Compliance	 with	 checklist	 use	 was	
variable	 across	 studies	 with	 no	 pattern	 of	 changing	 use	 over	 time	 (Supplementary	 table	 8).	 To	
















checklist	 use	 because	 of	 existing	 widespread	 implementation.	 Therefore,	 in	 the	 absence	 of	 data	
from	 randomised	 trials,	 our	 analyses	 may	 represent	 the	 highest	 currently	 attainable	 level	 of	
evidence	describing	the	effects	of	surgical	safety	checklist	use.	Future	randomised	trials	may	not	be	
possible,	but	 further	 research	should	be	standardised	 for	 individual	 compliance	with	 the	checklist.	
The	 findings	of	 the	 ISOS	analysis,	where	checklist	exposure	was	associated	with	 reduced	mortality	
but	not	complications,	contrasted	with	the	results	of	the	meta-analysis.	This	is	counterintuitive,	but	
not	uncommon	among	meta-analyses,	where	 the	 results	 of	 an	 individual	 study	may	 contrast	with	
the	overall	weighted	effect.	The	results	of	this	meta-analysis	suggest	that	across	a	range	of	studies	at	
many	 hospitals,	 checklist	 use	 is	 associated	 with	 fewer	 postoperative	 complications	 and	 deaths.	





European	hospitals,	 suggested	 that	checklist	exposure	was	associated	with	a	19%	reduction	 in	 the	






Our	 results	 are	 therefore	more	widely	 generalisable	 and	 indicate	 a	 need	 for	 research	 and	 quality	
improvement	 to	 ensure	 safe	 and	 effective	 patient	 care	 in	 low-	 and	 middle-income	 countries.	
Examples	may	 include	 rapid	 response	 systems	 and	 early	 warning	 scores.31-33	 The	 largest	 study	 to	
evaluate	 the	 surgical	 safety	 checklist	 to	 date	 was	 a	 cohort	 study	 of	 an	 implementation	 project	
performed	in	acute	care	hospitals	in	Canada.34	In	contrast	to	our	results,	the	authors	did	not	identify	
any	 benefit	 associated	 with	 checklist	 use,	 when	 comparing	 the	 three	 months	 before	 and	 after	
implementation	in	more	than	200,000	patients.	This	may	be	due	in	part	to	pre-existing	high-quality	
care	at	these	hospitals.	We	included	this	study	in	our	meta-analysis,	which	may	explain,	in	part,	the	
smaller	effect	estimates	 than	observed	 in	a	previous	 systematic	 review.12	Similarly,	 the	 findings	of	
the	 ISOS	 analysis	 contrast	 with	 the	 results	 of	 our	 meta-analysis,	 which	 identified	 a	 reduction	 in	
postoperative	complications	associated	with	checklist	exposure.	This	might	be	explained	by	the	high	






meta-analysis.	 ISOS	 is	 one	 of	 the	 largest	 prospective	 international	 cohort	 studies	 of	 surgical	
outcomes	conducted	to	date,	and	in	contrast	to	many	other	studies,	includes	data	from	low,	middle	
and	high-income	countries.6	Due	to	the	 large	number	of	patients	enrolled,	we	were	able	 to	adjust	
the	 analysis	 for	 a	 variety	 of	 potential	 confounding	 factors.	 Although,	 as	with	 any	 epidemiological	
study,	we	must	acknowledge	the	potential	influence	of	unmeasured	confounding.	The	meta-analysis	
included	more	than	ten	times	as	many	patients	as	the	previous	largest	evidence	synthesis,	and	the	





low-	 and	middle-income	 countries,	where	 there	was	 a	bias	 towards	university	hospitals	 and	away	
from	smaller	district	hospitals.	In	general,	we	would	expect	hospitals	that	participate	in	research	to	
offer	 a	 better	 standard	 of	 care,	 since	 research	 active	 hospitals	 tend	 to	 have	 superior	 clinical	
outcomes.35	There	is	likely	to	be	heterogeneity	of	surgical	and	perioperative	care	and	administrative	
procedures	 across	 hospitals	 included	 in	 the	 ISOS	 study,	 which	 may	 influence	 the	 results.	 For	
example,	hospitals	in	some	countries	may	discharge	patients	at	an	earlier	stage	of	the	postoperative	
pathway	 than	others,	which	may	 influence	 the	 rates	of	 recorded	 in-hospital	 complications.	 This	 is	
further	 illustrated	by	the	variation	in	compliance	with	the	checklist	at	a	country	 level,	where	three	
quarters	of	countries	used	the	checklist	 in	>89%	of	cases,	 in	contrast	to	wide	variation	 in	checklist	
use	among	countries	in	the	lowest	quartile	(27-85%).	However,	checklist	compliance	–	similar	to	the	




on	 the	use	of	 the	surgical	 safety	checklist	and	we	did	not	differentiate	between	different	 types	of	
complications	 in	 the	 analysis.	 The	 literature	 describing	 the	 checklist	 describes	 a	 variety	 of	
methodologies	 including	 randomised	 trials,	 prospective	 and	 retrospective	 cohort	 studies,	
implementation	 studies	 and	 natural	 trials.	 We	 performed	 a	 wide-ranging	 systematic	 review	 and	
meta-analysis	 to	 reflect	 the	 breadth	 of	 available	 knowledge.	 However,	 while	 we	 were	 able	 to	
increase	 the	 precision	 of	 our	 effect	 size	 estimates	 compared	 to	 previous	 studies,	 the	 population	
samples	 of	 included	 studies	 may	 be	 quite	 different,	 and	 this	 is	 reflected	 in	 the	 between	 study	
heterogeneity.	An	alternative	approach	is	to	undertake	a	meta-analysis	based	on	one	methodology	
only,	for	example	randomised	trials.	This	approach	has	been	helpful,	but	is	limited	by	the	number	of	










The	World	Health	Organisation	 and	 similar	 surgical	 safety	 checklists	 are	 simple	 tools,	 designed	 to	
improve	 the	 safety	 and	 quality	 of	 perioperative	 care.	 We	 have	 provided	 evidence	 that	 patients	
exposed	 to	 a	 surgical	 safety	 checklist	 experience	 better	 postoperative	 outcomes.	 However,	 it	
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		 Number	of	patients	(%)	 Checklist	use	(%)	 Did	not	use	checklist	(%)	 OR	(95%	CI)	 P	value	
	
n	=	44814	 n	=	40245	 n	=	4538	 -	 -	
Age,	Median	(IQR)	 57	(43	-	69)	 57	(43	-	69)	 56	(41	-	68)	 1.04	(0.87	-	1.23)	 0.70	
Male,	n(%)	 20	458	(45.7)	 18	317	(45.5)	 2	125	(46.8)	 0.95	(0.89	-	1.01)	 0.13	
Females,	n(%)	 24	351	(54.3)	 21	927	(54.5)	 2	413	(53.2)	 1.05	(0.98	-	1.13)	 0.13	
Present	smoker,	n(%)	 7	931	(17.8)	 6	942	(17.3)	 965	(12.2)	 1.04	(0.89	-	1.22)	 0.64	
ASA	Score	n	(%)	
	 	 	 	 	I	 11	227	(25.1) 9	973	(24.8) 1	246	(27.5) 0.97	(0.81	-	1.16) 0.72
II	 22	265	(49.8)	 20	300	(50.5)	 1	956	(43.2)	 1.08	(0.94	-	1.24)	 0.28	
III	 10	193	(22.8)	 8	991	(22.4)	 1	194	(26.4)	 1.06	(0.92	-	1.23)	 0.41	
IV	 1	038	(2.3)	 908	(2.3)	 130	(2.9)	 0.90	(0.66	-	1.23)	 0.51	
Grade	of	surgery,	n	(%)	
	 	 	 	 	Minor	 8	411	(18.8) 7	448	(18.5) 960	(21.2) 0.69	(0.63	-	0.77) <0.01
Intermediate	 20	203	(45.1)	 18	051	(44.9)	 2	137	(47.1)	 0.93	(0.86	-	1.01)	 0.11	
Major	 16	175	(36.1)	 14	732	(36.6)	 1	438	(31.7)	 1.54	(1.39	-	1.72)	 <0.01	
Surgical	Specialty,	n	(%)	
	 	 	 	 	Orthopaedic	 9	459	(21.1) 8	683	(21.6) 771	(17.0) 1.18	(1.01	-	1.39) 0.04
Breast	 1	538	(3.4)	 1	393	(3.5)	 145	(3.2)	 0.86	(0.63	-	1.18)	 0.34	
Obstetrics	&	Gynaecology	 5	674	(12.7)	 5	123	(12.7)	 547	(12.1)	 0.92	(0.75	-	1.12)	 0.40	
Urology	&	Kidney	 4	871	(10.9)	 4	299	(10.7)	 570	(12.6)	 0.92	(0.76	-	1.11)	 0.37	
Upper	Gastrointestinal	 1	986	(4.4)	 1	776	(4.4)	 208	(4.6)	 1.31	(0.99	-	1.73)	 0.06	
Lower	Gastrointestinal	 3	073	(6.9)	 2	711	(6.7)	 360	(7.9)	 1.06	(0.84	-	1.33)	 0.63	
Hepato-biliary	 2	282	(5.1)	 1	959	(4.9)	 322	(7.1)	 1.18	(0.91	-	1.53)	 0.22	
Vascular	 1	599	(3.6)	 1	436	(3.6)	 161	(3.6)	 1.17	(0.85	-	1.61)	 0.32	
23	
	
Head	and	neck	 6	510	(14.5)	 5	913	(14.7)	 592	(13.1)	 0.88	(0.74	-	1.03)	 0.11	
Plastic	or	cutaneous	 1	670	(3.7)	 1	386	(3.5)	 284	(6.3)	 1.01	(0.78	-	1.31)	 0.94	
Cardiac	 1	716	(3.8)	 1	557	(3.9)	 159	(3.5)	 0.54	(0.39	-	0.75)	 <0.01	
Thoracic	(lung	&	other)	 1	157	(2.6)	 1	086	(2.7)	 69	(1.5)	 1.44	(0.95	-	2.18)	 0.08	
Other	 3	270	(7.3)	 2	919	(7.3)	 350	(7.7)	 0.88	(0.72	-	1.09)	 0.24	
Laparoscopic	Surgery,	n(%)	 7	087	(15.8)	 6	472	(16.1)	 610	(13.5)	 1.37	(1.10	-	1.69)	 <0.01	
Comorbid	Disorder,	n(%)	
	 	 	 	 	Coronary	artery	disease	 4	588	(10.3) 3	952	(9.8) 632	(14.0) 1.17	(0.94	-	1.46) 0.16
Heart	Failure	 1	882	(4.2)	 1	594	(4.0)	 287	(6.3)	 0.93	(0.70	-	1.25)	 0.65	
Diabetes	Mellitus	 5	171	(11.6)	 4	596	(11.4)	 571	(12.6)	 0.85	(0.70	-	1.03)	 0.10	
Cirrhosis	 342	(0.8)	 311	(0.8)	 31	(0.7)	 1.15	(0.56	-	2.37)	 0.70	
Metastatic	cancer	 1	706	(3.8)	 1	547	(3.9)	 159	(3.5)	 0.90	(0.67	-	1.21)	 0.48	
Stroke	 1	492	(3.3)	 1	333	(3.3)	 158	(3.5)	 1.00	(0.72	-	1.39)	 0.99	
COPD	 4	094	(9.2)	 3	790	(9.4)	 303	(6.7)	 1.07	(0.85	-	1.35)	 0.55	
Other	 3269	(7.3)	 16	552	(41.2)	 2	042	(45.1)	 1.00	(0.87	-	1.16)	 0.95	
Had	a	complication	 7	508	(16.8)	 6	734	(16.7)	 768	(16.9)	 1.04	(0.87	-	1.23)	 0.70	















  Any	complication	 p-value	 Mortality	 p-value	
Age (years) 1.01	(1.00	-	1.01)	 <0.01	 1.03	(1.02	-	1.04)	 <0.01	
Male 1.05	(1.02	-	1.08)	 <0.01	 1.03	(0.89	-	1.21)	 0.67	
Female 	0.95	(0.93	-	0.98)		 <0.01	 0.97	(0.83	-	1.13)	 0.67	
Present smoker 0.99	(0.92	-	1.07)	 0.84	 1.61	(1.12	-	2.31)	 0.01	
ASA Score 
	 	 	 	I 0.54	(0.49	-	0.58) <0.01 0.09	(0.02	-	0.39) <0.01
II 0.71	(0.67	-	0.75)	 <0.01	 0.69	(0.39	-	1.22)	 0.20	
III 1.21	(1.14	-	1.29)	 <0.01	 2.20	(1.29	-	3.76)	 <0.01	
IV 2.17	(1.92	-	2.46)	 <0.01	 7.54	(4.18	-	13.63)	 <0.01	
Grade of surgery 
	 	 	 	Minor 0.52	(0.49	-	0.56) <0.01 0.63	(0.43	-	0.93) 0.02
Intermediate 0.91	(0.87	-	0.96)	 <0.01	 0.92	(0.71	-	1.21)	 0.55	
Major 2.10	(2.00	-	2.20)	 <0.01	 1.72	(1.34	-	2.22)	 <0.01	
Surgical Specialty 
	 	 	 	Orthopaedic 0.89	(0.83	-	0.96) <0.01 0.64	(0.41	-	0.98) 0.04
Breast 0.59	(0.49	-	0.70)	 <0.01	 0.65	(0.17	-	2.42)	 0.52	
Obstetrics & Gynaecology 0.77	(0.69	-	0.85)	 <0.01	 0.80	(0.36	-	1.76)	 0.57	
Urology & Kidney 0.83	(0.76	-	0.91)	 <0.01	 0.48	(0.26	-	0.89)	 0.02	
Upper Gastrointestinal 1.37	(1.23	-	1.53)	 <0.01	 2.79	(1.85	-	4.22)	 <0.01	
Lower Gastrointestinal 1.48	(1.34	-	1.62)	 <0.01	 1.90	(1.27	-	2.84)	 <0.01	
Hepato-biliary 0.97	(0.86	-	1.10)	 0.67	 1.61	(0.93	-	2.78)	 0.09	
Vascular 1.05	(0.93	-	1.19)	 0.42	 0.96	(0.56	-	1.64)	 0.87	
Head and neck 0.67	(0.62	-	0.74)	 <0.01	 0.63	(0.36	-	1.11)	 0.11	
Plastic or cutaneous 1.01	(0.88	-	1.17)	 0.85	 0.94	(0.39	-	2.23)	 0.88	
Cardiac 2.49	(2.20	-	2.80)	 <0.01	 1.47	(0.95	-	2.28)	 0.09	
Thoracic (lung & other) 1.25	(1.08	-	1.45)	 <0.01	 1.19	(0.63	-	2.26)	 0.59	
Other 0.68	(0.60	-	0.77)	 <0.01	 0.76	(0.37	-	1.58)	 0.46	
Comorbid Disorder 
	 	 	 	Coronary artery disease 1.04	(0.95	-	1.13) 0.44 0.99	(0.70	-	1.40) 0.96
Heart Failure 1.28	(1.13	-	1.44)	 <0.01	 1.59	(1.08	-	2.32)	 0.02	
Diabetes Mellitus 1.10	(1.01	-	1.19)	 0.02	 1.24	(0.89	-	1.73)	 0.20	
Cirrhosis 1.45	(1.11	-	1.88)	 <0.01	 2.77	(1.34	-	5.72)	 <0.01	
Metastatic cancer 1.45	(1.28	-	1.64)	 <0.01	 3.41	(2.25	-	5.19)	 <0.01	
Stroke 1.16	(1.01	-	1.32)	 0.03	 2.79	(1.88	-	4.14)	 <0.01	
COPD 1.13	(1.04	-	1.24)	 <0.01	 1.13	(0.78	-	1.64)	 0.52	
Other 1.23	(1.15	-	1.31)	 <0.01	 1.47	(1.07	-	2.01)	 0.02	








complication	 (excluding	 mortality).	 Generalised	 linear	 models,	 with	 results	 presented	 as	 odds	 ratios	 with	 95%	
confidence	intervals	and	p-values.	All	variables	were	binary	categorical	unless	otherwise	stated,	where	exposure	to	the	
variable	was	 compared	 to	 non-exposure.	 Checklist	 compliance,	 ASA	 score	 and	 grade	 of	 surgery	 categorical	 variables	
where	 the	 reference	was	 the	average	effect	 across	 the	whole	 cohort.	 COPD,	Chronic	Obstructive	Pulmonary	Disease;	
ASA,	American	Society	of	Anesthesiologists.	
		 Any	complication	 p-value	 Mortality	 P-value	
Age	(years)	 1.01	(1.00	-	1.01)	 <0.01	 1.03	(1.02	-	1.05)	 <0.01	
Male	 1.05	(1.02	-	1.08)	 <0.01	 1.05	(0.90	-	1.22)	 0.58	
Female	 0.95	(0.93	-	0.98)	 <0.01	 0.96	(0.82	-	1.12)	 0.58	
Present	smoker	 0.99	(0.92	-	1.07)	 0.84	 1.58	(1.10	-	2.27)	 0.01	
ASA	Score	
	 	 	 	I	 0.54	(0.49	-	0.58) <0.01 0.09	(0.02	-	0.40) <0.01
II	 0.71	(0.67	-	0.75)	 <0.01	 0.72	(0.41	-	1.26)	 0.25	
III	 1.21	(1.14	-	1.29)	 <0.01	 2.21	(1.29	-	3.78)	 <0.01	
IV	 2.17	(1.92	-	2.46)	 <0.01	 7.02	(3.87	-	12.74)	 <0.01	
Grade	of	surgery	
	 	 	 	Minor	 0.52	(0.49	-	0.56) <0.01 0.64	(0.43	-	0.94) 0.02
Intermediate	 0.91	(0.87	-	0.96)	 <0.01	 0.91	(0.70	-	1.19)	 0.5	
Major	 2.10	(2.00	-	2.20)	 <0.01	 1.72	(1.33	-	2.22)	 <0.01	
Surgical	Specialty	
	 	 	 	Orthopaedic	 0.89	(0.83	-	0.96) <0.01 0.65	(0.42	-	0.99) 0.05
Breast	 0.59	(0.49	-	0.70)	 <0.01	 0.64	(0.17	-	2.40)	 0.51	
Obstetrics	&	Gynaecology	 0.77	(0.69	-	0.85)	 <0.01	 0.83	(0.37	-	1.84)	 0.65	
Urology	&	Kidney	 0.83	(0.76	-	0.91)	 <0.01	 0.49	(0.26	-	0.91)	 0.02	
Upper	Gastrointestinal	 1.37	(1.23	-	1.53)	 <0.01	 2.69	(1.78	-	4.08)	 <0.01	
Lower	Gastrointestinal	 1.48	(1.35	-	1.62)	 <0.01	 1.89	(1.26	-	2.83)	 <0.01	
Hepato-biliary	 0.98	(0.86	-	1.10)	 0.69	 1.49	(0.86	-	2.58)	 0.16	
Vascular	 1.05	(0.93	-	1.19)	 0.45	 0.97	(0.57	-	1.66)	 0.92	
Head	and	neck	 0.67	(0.62	-	0.73)	 <0.01	 0.62	(0.35	-	1.10)	 0.11	
Plastic	or	cutaneous	 1.01	(0.88	-	1.17)	 0.88	 0.95	(0.40	-	2.26)	 0.91	
Cardiac	 2.49	(2.20	-	2.81)	 <0.01	 1.60	(1.03	-	2.49)	 0.04	
Thoracic	(lung	&	other)	 1.25	(1.08	-	1.45)	 <0.01	 1.15	(0.61	-	2.19)	 0.66	
Other	 0.68	(0.60	-	0.77)	 <0.01	 0.74	(0.36	-	1.54)	 0.43	
Comorbid	Disorder	
	 	 	 	Coronary	artery	disease	 1.03	(0.94	-	0.13) 0.48 0.98	(0.69	-	1.39) 0.91
Heart	Failure	 1.27	(1.13	-	1.44)	 <0.01	 1.47	(1.00	-	2.16)	 0.05	
Diabetes	Mellitus	 1.10	(1.01	-	1.19)	 0.03	 1.26	(0.90	-	1.75)	 0.18	
Cirrhosis	 1.45	(1.11	-	1.88)	 <0.01	 2.72	(1.31	-	5.63)	 <0.01	
Metastatic	cancer	 1.45	(1.28	-	1.64)	 <0.01	 3.41	(2.24	-	5.19)	 <0.01	
Stroke	 1.15	(1.01	-	1.32)	 0.03	 2.80	(1.88	-	4.16)	 <0.01	
COPD	 1.13	(1.04	-	1.24)	 <0.01	 1.18	(0.81	-	1.72)	 0.38	
Other	 1.22	(1.15	-	1.31)	 <0.01	 1.42	(1.03	-	1.94)	 0.03	
Checklist	compliance	
	 	 	 	Quartile	1	(low)	 1.07	(0.94	-	1.23) 0.32 1.80	(1.34	-	2.41) <0.01
Quartile	2	(medium)	 1.17	(1.00	-	1.36)	 0.04	 1.02	(0.73	-	1.41)	 0.93	
Quartile	3	(high)	 0.87	(0.75	-	1.02)	 0.09	 0.90	(0.61	-	1.32)	 0.58	








Study	reference	 In	prior	review?	 Multicentre	 Study	design	 Population	
Number	of	Patients	 Outcomes	
No	
checklist	 Checklist	 Mortality	 Complications	
Askarian	M38	 Y	 N	 Before/After	 GS	 144	 150	 NO	 YES	
Bliss	A39	 Y	 N	 Case/Control	 GIS/Amputations	 2079	 73	 NO	 YES	
Haynes	B40		 Y	 Y	 Before/After	 NCS	 3733	 3955	 YES	 YES	
Jammer	I14	 N	 Y	 Prospective	Cohort	 NCS	 15286	 31038	 YES	 NO	
Lacassie	J30		 N	 N	 Retrospective	Cohort	 Any	Surgery	 40781	 29858	 YES	 NO	
Lepanuluoma41	 N	 N	 Retrospective	Cohort	 Neurosurgery	 2665	 2753	 NO	 YES	
Lubbeke	A42		 N	 N	 Before/After	 GS,	US,	Day	Surgery,	elective	 609	 1818	 YES	 YES	
Mayer	EK43	 N	 Y	 Longitudinal		 GS,	US,	OS	 220	 6494	 Yes	 YES	
Urbach	R34	 N	 Y	 Before/After	 Any	procedure	 109341	 106370	 YES	 YES	
van	Klei	WA44	 Y	 N	 Retrospective	cohort	 Non-day	case	surgery	 14362	 11151	 YES	 NO	
ISOS	Group	 N	 Y	 Prospective	Cohort	 Inpatient,	elective	surgery	 4538	 40245	 YES	 YES	
	
	 		
